Drug Profile
Research programme: AXL kinase inhibitors - BerGenBio
Alternative Names: BGB 001; BGB 002 target; BGB 003; BGB 109; BGB 10C9; BGB-101Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator BerGenBio
- Class Antineoplastics; Immunoconjugates; Immunotherapies; Monoclonal antibodies; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Pancreatic cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Cancer in Norway (Parenteral)
- 17 Feb 2022 AXL kinase inhibitors - BerGenBio is available for licensing as of 17 Feb 2022. https://www.bergenbio.com/company/partnering/
- 16 Feb 2022 Preclinical development is still ongoing for Cancer in Norway